Navigation Links
Telik Announces Presentation and Webcast at Needham Biotechnology Conference
Date:6/5/2008

PALO ALTO, Calif., June 5 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate overview at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference in New York City on Wednesday, June 11, 2008 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, http://www.telik.com.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces First Quarter 2008 Financial Results
2. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
3. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
4. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
7. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
8. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
9. Biopure Announces MHRA Meeting Update
10. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
11. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies ... options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, launched ... space at 3624 Market Street. , Vironika is developing a treatment for a ...
(Date:1/19/2017)... 2017 Research and Markets has announced the ... Cancer Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... market is projected to reach $15,737 million by 2022 from $6,521 ... 2022. Omic technologies segment accounted for more than ...
(Date:1/19/2017)... Basel, Switzerland (PRWEB) , ... ... ... leading provider of advanced software solutions for pharmaceutical research and development (R&D), ... project-based expertise in omic data analysis and interpretation for the rapidly evolving ...
(Date:1/19/2017)... ... 2017 , ... The American Medical Informatics Association (AMIA) today ... Policy. Specifically, the nation’s leading informatics experts, said data sharing plans should be ... recommended that NIH earmark funding for researchers to produce and execute data sharing ...
Breaking Biology Technology:
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016  Singulex, Inc., ... Molecule Counting technology, entered into a license and supply ... serving science. The agreement provides Singulex access to Thermo ... Europe is used to diagnose systemic ... United States to aid in assessing the ...
Breaking Biology News(10 mins):